Media headlines about Smith & Nephew (NYSE:SNN) have trended somewhat positive on Wednesday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Smith & Nephew earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.2628402126123 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Smith & Nephew (NYSE:SNN) traded down $0.04 on Wednesday, hitting $35.81. The stock had a trading volume of 681,687 shares, compared to its average volume of 604,657. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.03 and a quick ratio of 1.06. Smith & Nephew has a 52 week low of $30.19 and a 52 week high of $40.43.

The company also recently announced a None dividend, which will be paid on Wednesday, May 9th. Stockholders of record on Friday, April 6th will be paid a $0.444 dividend. The ex-dividend date of this dividend is Thursday, April 5th.

A number of equities research analysts have recently weighed in on SNN shares. Zacks Investment Research lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Morgan Stanley lowered Smith & Nephew from an “overweight” rating to an “equal weight” rating in a research report on Monday, December 11th. Canaccord Genuity restated a “buy” rating and issued a $45.00 target price on shares of Smith & Nephew in a research note on Friday, January 5th. JPMorgan Chase & Co. upgraded Smith & Nephew from a “neutral” rating to an “overweight” rating in a research note on Thursday, January 25th. Finally, ValuEngine cut Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $44.00.

COPYRIGHT VIOLATION WARNING: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at

Smith & Nephew Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Insider Buying and Selling by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.